CIK 0001821586 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in E9 · fiscal year ends 12/31
| FY2025 | FY2024 | FY2021 | |
|---|---|---|---|
| Net income (USD) | -4.5 M | ||
| Diluted EPS (USD/shares) | -3.53 | -1.7 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-30 | 8-K | CURRENT REPORT items 8.01 | 2026-09-30 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-10 | S-8 | REGISTRATION STATEMENT | |
| 2026-08-10 | S-3ASR | REGISTRATION STATEMENT | |
| 2026-08-10 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-10 | 8-K | CURRENT REPORT items 2.02,7.01,9.01 | 2026-08-10 |
| 2026-07-29 | 4 | 4 | 2026-07-27 |
| 2026-07-23 | 4 | 4 | 2026-07-21 |
| 2026-07-21 | 4 | 4 | 2026-07-20 |
| 2026-07-20 | 4 | 4 | 2026-07-15 |
| 2026-07-15 | 144 | 144 | |
| 2026-07-15 | 8-K | CURRENT REPORT items 8.01 | 2026-07-14 |
| 2026-07-13 | 4 | 4 | 2026-07-09 |
| 2026-07-02 | 4 | 4 | 2026-07-01 |
| 2026-06-30 | 144 | 144 | |
| 2026-06-29 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-06-25 | 8-K | CURRENT REPORT items 1.01,9.01 | 2026-06-23 |
| 2026-06-24 | 424B5 | PROSPECTUS SUPPLEMENT | |
| 2026-06-23 | 4 | 4 | 2026-06-22 |
| 2026-06-22 | 424B5 | PRELIMINARY PROSPECTUS SUPPLEMENT | |
| 2026-06-22 | 4 | OWNERSHIP DOCUMENT | 2026-06-17 |
| 2026-06-22 | 8-K | CURRENT REPORT items 7.01,8.01,9.01 | 2026-06-21 |
| 2026-06-18 | 4 | 4 | 2026-06-17 |
Forms on file (last 1,000): 4 81, 8-K 53, 10-Q 18, 3 16, SC 13G/A 15, UPLOAD 14, CORRESP 14, 144 13. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MLTX (0.002 USD), /gw/filings/filings?ticker=MLTX&form=8-K, /gw/filings/facts?ticker=MLTX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange